Repurposing of Linagliptin and Similar FDA Approved Drugs as Antidiabetic Agents

    Studysummary This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Related research 1

    1. Repurposing of Linagliptin and Similar FDA Approved Drugs as Antidiabetic Agents Letters in Applied NanoBioScience · 2021